ATLANTA, GA — Despite promise for improving heart failure (HF) in pilot studies, an interatrial shunt (IAS) device did not meet the primary composite efficacy endpoint in a pivotal trial, a result ...

ATLANTA -- An interatrial shunt failed to provide a clinical benefit to people with heart failure (HF) overall in the RELIEVE-HF trial, though actual harm or benefit seemed to hinge on the patient's ...

Madison Scientific, a Chicago-based startup developing a SmartShunt device, has raised $7 million in seed funding. The private medical device company said in a press release today that funding was ...

PHOENIX -- The functional and quality-of-life benefits of creating a left-to-right shunt in the interatrial septum to offload failing hearts held up over the midterm in a series of small feasibility ...

BOSTON, MA—This week’s Technology and Heart Failure Therapeutics (THT) 2023 meeting featured more than a dozen talks on interatrial shunts to reduce left atrial pressures and volume overload in heart ...

10 patients enrolled with 100% implantation success Adona's adjustable interatrial shunt is designed so it can be modified post-implantation to provide a more adaptive and personalized lifetime ...

Heart failure with preserved ejection fraction (HFpEF) can arise from a range of genetic and physiological triggers, but the common denominator—elevated left atrial (LA) pressure—has spawned a host of ...

Findings from an echocardiographic study of patients with heart failure with preserved or mildly reduced ejection fraction treated with an atrial shunt have shed more light on mechanisms that explain ...